Compare VECO & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VECO | NAMS |
|---|---|---|
| Founded | 1945 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | 100 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 4.1B |
| IPO Year | 1996 | N/A |
| Metric | VECO | NAMS |
|---|---|---|
| Price | $57.78 | $34.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $27.25 | ★ $46.75 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $664,294,000.00 | N/A |
| Revenue This Year | $16.39 | $17.96 |
| Revenue Next Year | $12.40 | $540.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $19.29 | $20.53 |
| 52 Week High | $86.63 | $42.21 |
| Indicator | VECO | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 61.14 |
| Support Level | $53.50 | $33.83 |
| Resistance Level | $64.92 | $37.27 |
| Average True Range (ATR) | 6.26 | 1.53 |
| MACD | -1.97 | 0.57 |
| Stochastic Oscillator | 3.40 | 79.16 |
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The maximum of the company's revenue is generated from sales to the Semiconductor Industry and within China.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.